{"id":"W4394015334","doi":"10.1016/j.euo.2024.03.006","title":"Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Tolerability; Prostate cancer; Placebo; Adverse effect; Abiraterone; Internal medicine; Oncology; Enzalutamide; Prednisone; Common Terminology Criteria for Adverse Events; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007961994,0.0002146161,0.000524371,0.00009574588,0.00005774211,0.00002046782,0.0001422217,0.00005046948,0.00009743311],"category_scores_gemma":[0.00008606585,0.000104267,0.00004228464,0.0003133619,0.0006002117,0.00007331667,0.00004896634,0.0004353984,0.00002146413],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001799209,"about_ca_system_score_gemma":0.0008148052,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004347441,"about_ca_topic_score_gemma":0.001140415,"domain_scores_codex":[0.9972344,0.001054106,0.0005805376,0.0005223936,0.0002585232,0.0003500388],"domain_scores_gemma":[0.9987732,0.00040173,0.0001679365,0.0003845967,0.0001806371,0.00009195842],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9464095,0.003659389,0.02584494,0.00008755164,0.0007561584,0.001256952,0.006083884,0.00008744943,0.001050937,0.00003480098,0.0006854403,0.01404299],"study_design_scores_gemma":[0.5570963,0.1145237,0.315161,0.0002176571,0.000831034,0.00001521308,0.000383727,0.0002661101,0.0005587144,0.00008025492,0.01057638,0.0002899064],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877815,0.0005698949,0.000007302824,0.006988218,0.0001962151,0.002748377,0.0004288665,0.00004127394,0.001238406],"genre_scores_gemma":[0.9985388,0.00004626905,0.000144766,0.000240056,0.00008357762,0.0001371433,0.000378443,0.00004217091,0.0003887758],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3893132,"threshold_uncertainty_score":0.4251884,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03318067851103599,"score_gpt":0.3274725378897915,"score_spread":0.2942918593787555,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}